|Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France. email@example.com|
|Abstract||Review on t(2;2)(p22;p22) and del(2)(p22p22) LTBP1/BIRC6 in breast and lung cancers, with data on the genes involved.|
|Phylum||Female organs: Breast::Carcinoma|
|Clinics and Pathology|
|Note||Only two cases to date of t(2;2)(p22;p22) or del(2)(p22p22) LTBP1/BIRC6 in solid tumors, without further data; it has been described in a case of breast carcinoma, and in a case of lung squamous cell carcinoma (Yoshihara et al., 2015). Note: t(2;2)(p22;p22) or del(2)(p22p22) LTBP1/BIRC6 in acute myeloid leukemia has also been found found in two cases.|
|Epidemiology||Invasive breast cancer is the most common carcinoma in women, accounting for 22% of all female cancers. One million women worldwide are diagnosed with breast cancer every year (Carcangiu et al. 2005).|
|Pathology||The most common histologic type of invasive breast carcinoma is designated as ductal carcinoma (80% of all cases), with many morphologic variants. Invasive lobular carcinoma is the second major type (5-10%) of breast cancer (Carcangiu et al. 2005).|
|Disease||Squamous cell lung carcinoma|
|Epidemiology||Squamous cell carcinoma is the most frequent lung cancer in male patients, representing about 40% of the cases, and only 25% in women (much less frequent in female patients than adenocarcinoma). Squamous cell carcinoma is the lung cancer the most often associated with tobacco smoking. Location of the tumour is usually central, present as a perihilar mass, with or without lobar collapse and obstructive pneumonitis, but it can also be peripheral at times.|
|Pathology||There are small cell variants (differential diagnosis: SCLC), clear cell variants, well-differentiated papillary variants, basaloid variants with a very aggressive clinical course, and spindle cell (sarcomatoid) carcinosarcoma variants of the typical squamous cell carcinoma. The expression of cytokeratins (CK) CK5/6, CK34BE12 and TP63 (3q28, also called P63) are strong in squamous cell carcinoma, whereas the expression of CK7 and NKX2-1 (14q13, also called TTF-1) are strong in adenocarcinoma (Xu et al., 2014).|
|Genes involved and Proteins|
|Gene Name||BIRC6 (Baculoviral IAP repeat-containing 6)|
|Protein|| BIRC6 contains two domains: a N-terminal BIR repeat (needed for interactions with caspases and IAP-binding motif (IBM) containing proteins) and a C-terminal UBC domain (which can form a thiolester linkage with ubiquitin transferred by E1).|
Inhibitor of apoptosis: BIRC6 is a peripheral membrane protein of the trans-Golgi network that protects cells from apoptosis
BIRC6 and treatment resistance: Silencing of BIRC6 has been shown to sensitize cancer cells to various anticancer agents
BIRC6 is essential in embryonic development.
Regulator of cytokinesis: BIRC6 is a major regulator of abscission, the final stage of cytokinesis.
Regulator of mitosis: BIRC6 interacts with CCNA2 (cyclin A) and promotes its degradation in early mitosis
(Iris Luk and Wang, 2014).
BIRC6 is involved in myelodysplastic syndromes and acute myeloid leukemias, colorectal cancer, neuroblastoma, skin melanoma, non-small cell lung cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma and breast cancer.
|Gene Name||LTBP1 (latent transforming growth factor beta binding protein 1)|
|Dna / Rna||Eleven splice variants.|
|Protein|| 1721 amino acids; belongs to the LTBP/fibrillin family. |
LTBP1 is composed of a signal peptide: (amino acids 1-23), 18 epidermal growth factor (EGF)-like repeats and four cysteines rich domains, the TB (TGFb binding protein-like) domains. The LTBP1 C-terminus interacts with the extracellular matrix via fibrillin microfibrils. EGF-like repeats provide stability to the protein structure
TGFB1 is secreted as a biologically latent complex composed of LTBP1, a latency associated peptide (LAP), (LAP is the TGFB1 pro-peptide which regulates latency, that is cleaved intracellularly prior to secretion), and the TGFB1 cytokine. LTBP1 plays roles in facilitating the folding and secretion of TGFB1 from the cell, and activation.
LTBP1 interacts with FBN1 (fibrillin 1). This interaction allows LTBP1 to sequester TGFB1 to fibrillin microfibrils; EFEMP2 (EGF containing fibulin-like extracellular matrix protein 2, or fibulin4) and ADAMTSL proteins form ternary complexes with LTBP1 and fibrillin.
LTBP1 is involved in epithelial-mesenchymal interaction and epithelial differentiation (Mazzieri et al., 2005; Robertson et al., 2014).
|Result of the chromosomal anomaly|
|Description||5' LTBP1 - 3' BIRC6|
|Breast tumors: an overview|
|Carcangiu, ML ; Casalini, P ; Ménard, S.|
|Atlas Genet Cytogenet Oncol Haematol. 2005;9(4):331-337.|
|BIRC6 (Baculoviral IAP repeat-containing 6);|
|Jentsch, S ; Pohl, C.|
|Atlas Genet Cytogenet Oncol Haematol. http://atlasgeneticsoncology.org/Genes/BIRC6ID798ch2p22.html|
|Expression of truncated latent TGF-beta-binding protein modulates TGF-beta signaling.|
|Mazzieri R, Jurukovski V, Obata H, Sung J, Platt A, Annes E, Karaman-Jurukovska N, Gleizes PE, Rifkin DB.|
|J Cell Sci. 2005 May 15;118(Pt 10):2177-87.|
|NMR spectroscopic and bioinformatic analyses of the LTBP1 C-terminus reveal a highly dynamic domain organisation.|
|Robertson IB, Handford PA, Redfield C.|
|PLoS One. 2014 Jan 29;9(1):e87125. doi: 10.1371/journal.pone.0087125.|
|Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: Utility of an immunohistochemical panel containing CK5/6, CK34bE12, p63, CK7 and TTF-1.|
|Xu XY, Yang GY, Yang JH, Li J.|
|Pathol Res Pract. 2014 Oct;210(10):680-5. doi: 10.1016/j.prp.2014.06.021. Epub 2014 Jul 1.|
|The landscape and therapeutic relevance of cancer-associated transcript fusions.|
|Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG.|
|Oncogene. 2015 Sep 10;34(37):4845-54. doi: 10.1038/onc.2014.406. Epub 2014 Dec 15.|
|This paper should be referenced as such :|
|Atlas Genet Cytogenet Oncol Haematol. in press|
|On line version : http://AtlasGeneticsOncology.org/Tumors/t0202p22p22ID5476.html|
|Translocations implicated (Data extracted from papers in the Atlas)|
|Mitelman database||t(2;2)(p22;p22) LTBP1/BIRC6 [Case List] t(2;2)(p22;p22) LTBP1/BIRC6 [Association List] Mitelman database (CGAP - NCBI)|
|arrayMap||arrayMap ((UZH-SIB Zurich) [auto + random 100 samples .. if exist ] [tabulated segments]|
|Disease database||del(2)(p22p22) LTBP1/BIRC6|
|REVIEW articles||automatic search in PubMed|
|Last year articles||automatic search in PubMed|
|© Atlas of Genetics and Cytogenetics in Oncology and Haematology||indexed on : Tue Sep 26 12:37:25 CEST 2017|
For comments and suggestions or contributions, please contact us